semaj83/ctmatch_classification huggingface dataset:
Patient description: A 62 yo male presents with four days of non-productive cough and one day of fever. He is on immunosuppressive medications, including prednisone. He is admitted to the hospital, and his work-up includes bronchoscopy with bronchoalveolar lavage (BAL). BAL fluid examination reveals owl's eye inclusion bodies in the nuclei of infection cells.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Patients Scheduled for Bronchoscopy Patients undergoing Fiberoptic Bronchoscopy for any indication and signing an informed consent form  Hypoxemia < 90% at Room air
Patient description: A 62 yo male presents with four days of non-productive cough and one day of fever. He is on immunosuppressive medications, including prednisone. He is admitted to the hospital, and his work-up includes bronchoscopy with bronchoalveolar lavage (BAL). BAL fluid examination reveals owl's eye inclusion bodies in the nuclei of infection cells.

Clinical trial eligibility criteria: eligible ages (years): 13.0-49.0,  Influenza, Human HIV Malaria Tetanus Polio Resident of HDSS village Singleton pregnancy Second or third trimester (after quickening) but before 33 weeks of gestation by fundal height Does not plan to relocate out of the HDSS area or population-based surveillance site in the next 12 months and agrees to all follow-up visits/contact by phone Is not currently enrolled in another intervention study Provides informed consent by signature or thumb print Consents to HIV testing and counseling as required Willing to deliver in the labor ward of the study hospital No history of chronic illness requiring multiple hospitalizations or prolonged medical therapy (except HIV on ART)  History of allergic reaction to any component of the study vaccines Residence outside the study area or planning to relocate out in the 9 months following enrollment Received immunoglobulin or blood products within 45 days of study entry Used immunosuppressive medication within 45 days of study entry (inhaled and topical corticosteroids permitted) High risk pregnancy including any pre-existing condition likely to cause complications of pregnancy (hypertension, diabetes, current asthma, eclampsia or pre-eclampsia, epilepsy, heart disease, renal disease, liver disease, fistula repair, leg or spine deformity) Unable to give informed consent (for example due to mental disability) Previous enrollment in a study with similar interventions Gestational age >32 weeks by last menstrual period or fundal height Acutely ill with temperature ≥37.5°C on the day of randomization/vaccination Hemoglobin <7.0 g/dL
Patient description: A 62 yo male presents with four days of non-productive cough and one day of fever. He is on immunosuppressive medications, including prednisone. He is admitted to the hospital, and his work-up includes bronchoscopy with bronchoalveolar lavage (BAL). BAL fluid examination reveals owl's eye inclusion bodies in the nuclei of infection cells.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Aplastic Anemia Main diagnosis: aplastic anemia Absence of severe and/or uncontrolled comorbidities Confirmed iron overload (serum ferritin ≥ 1000 mkg/L) Serum creatinine is not higher than the upper limit of normal for the given age Absence of severe proteinuria. Protein/Creatinine ratio should be < 0.5 mg/mg Liver enzymes are < 5 ULN Completion of a scheduled cycle of immunosuppressive treatment program, with no severe infectious or generalized hemorrhagic complications WHO (ECOG) performance status ≤ 2  No signed informed consent form Patient is under 18 years old Severe concomitant condition Severe infectious and generalized haemorrhagic complication following regular planned cycle of programmed immune suppressive treatment History of increased sensitivity to active substance and any other ingredient of the medicinal product Creatinine clearance (CC) < 60 ml/min and/or creatinine concentration in blood serum is 2 or more times higher than upper limit of age normal by results of 2 tests at Visits 1 and 2 Severe liver disorders (class C by Child-Pugh scale) Patients with aplastic anaemia in which chelator treatment will be ineffective due to rapid progression of the disease Significant proteinuria basing on protein creatinine ratio > 1.0 mg/ml in urine sample from second urination at Visits 1 and 2 (or as an alternative in 2 of 3 urine samples at screening) Rare hereditary disorders related to galactose intolerance, severe deficit of lactase or glucose-galactose malabsorption
Patient description: A 62 yo male presents with four days of non-productive cough and one day of fever. He is on immunosuppressive medications, including prednisone. He is admitted to the hospital, and his work-up includes bronchoscopy with bronchoalveolar lavage (BAL). BAL fluid examination reveals owl's eye inclusion bodies in the nuclei of infection cells.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Infection in Solid Organ Transplant Recipients Informed consent Male/female patients at least 18 years old who will be followed at our outpatient clinic for at least one year Recipients of first or repeat kidney transplants from living or deceased donors  Recipients of any combined transplant (kidney/pancreas, kidney liver) Unlikely to comply with the requirements of the study
Patient description: A 62 yo male presents with four days of non-productive cough and one day of fever. He is on immunosuppressive medications, including prednisone. He is admitted to the hospital, and his work-up includes bronchoscopy with bronchoalveolar lavage (BAL). BAL fluid examination reveals owl's eye inclusion bodies in the nuclei of infection cells.

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Postoperative Complications Undergoing laparoscopic gastric bypass surgery and included in the Scandinavian Obesity Surgery Registry  Undergoing other bariatric procedure than laparoscopic gastric bypass. Revisional surgery is excluded Lost to follow up
Patient description: A 62 yo male presents with four days of non-productive cough and one day of fever. He is on immunosuppressive medications, including prednisone. He is admitted to the hospital, and his work-up includes bronchoscopy with bronchoalveolar lavage (BAL). BAL fluid examination reveals owl's eye inclusion bodies in the nuclei of infection cells.

Clinical trial eligibility criteria: eligible ages (years): 20.0-999.0,  Allogeneic Hematopoietic Cell Transplant Subject is planned to undergo either of the following Sibling Donor Transplant 8 Human Leukocyte Antigen (HLA)-A, -B, -C, -DRß1 match utilizing high resolution typing or 8/8 (HLA)-A, -B, -C, -DRß1 match utilizing low or high resolution typing Unrelated Donor Transplant 8 or 8/8 HLA-A, -B, -C, -DRß1 match utilizing high resolution typing Subject has one of the following underlying diseases: Acute myeloid leukemia (AML) /Acute lymphoblastic leukemia (ALL) / Acute undifferentiated leukemia (AUL) /Acute biphenotypic leukemia / Chronic myelogenous leukemia (CML) / Chronic lymphocytic leukemia (CLL) / myelodysplastic syndrome(s) (MDS) Subject is scheduled to receive an allogeneic peripheral blood stem cell (PBSC) or bone marrow transplant (BMT) for the treatment of hematologic disorders  Subject has active CMV disease or infection or has received treatment for active CMV disease or infection within 90 days prior to transplant Subject has planned CMV prophylactic therapy with antiviral drugs or CMV-specific immunoglobulins Subject has a modified hematopoietic cell transplant comorbidity index (HCT-CI) score > 3 Subject is known to be positive for human immunodeficiency virus (HIV), hepatitis B surface antigen or hepatitis C ribonucleic acid (RNA) Subject has received any of the following substances or treatments T-cell depletion of donor cell product Alemtuzumab within 60 days prior to transplant, including conditioning regimen. Subjects for whom treatment with alemtuzumab is planned at any time from 60 days prior to through one year post-transplant should not be enrolled in the trial Administration of a CMV vaccine, including any prior exposure to ASP0113 Subject has received an allogeneic stem cell transplant within one year prior to transplant Subject has a current malignancy in addition to the malignancy being treated for the study or the subject has a history of any other malignancy
Patient description: A 62 yo male presents with four days of non-productive cough and one day of fever. He is on immunosuppressive medications, including prednisone. He is admitted to the hospital, and his work-up includes bronchoscopy with bronchoalveolar lavage (BAL). BAL fluid examination reveals owl's eye inclusion bodies in the nuclei of infection cells.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  EBV Infection CMV Infection Adenoviral Infection Prior myeloablative or non-myeloablative allogeneic hematopoietic stem cell transplant using either bone marrow, peripheral blood stem cells or single or double umbilical cord blood CMV, adenovirus or EBV infection persistent despite standard therapy For CMV infection Patients with CMV disease: defined as the demonstration of CMV by biopsy specimen from visceral sites (by culture or histology) or the detection of CMV by culture or direct fluorescent antibody stain in bronchoalveolar lavage fluid in the presence of new or changing pulmonary infiltrates OR Failure of antiviral therapy: defined as the continued presence of pp65 antigenemia (>1+ cell/100,000 cells) or DNAemia (as defined by reference lab performing PCR assay but usually >400 copies/ml) after at least 7 days of antiviral therapy OR Relapse after antiviral therapy defined as recurrence of either pp65 antigenemia or DNAemia after at least 2 weeks of antiviral therapy For CMV infection, standard therapy is defined as 7 days therapy with Ganciclovir, Foscarnet or Cidofovir for patients with disease or recurrence after 14 days therapy For EBV infection EBV infection is defined as Biopsy proven lymphoma with EBV genomes detected in tumor cells by immunocytochemistry or in situ PCR OR  Received ATG, or Campath or other immunosuppressive T cell monoclonal antibodies within 28 days of screening for enrollment Uncontrolled infections. For bacterial infections, patients must be receiving definitive therapy and have no signs of progressing infection for 72 hours prior to enrollment. For fungal infections patients must be receiving definitive systemic anti-fungal therapy and have no signs of progressing infection for 1 week prior to enrollment Progressing infection is defined as hemodynamic instability attributable to sepsis or new symptoms, worsening physical signs or radiographic findings attributable to infection. Persisting fever without other signs or symptoms will not be interpreted as progressing infection Received donor lymphocyte infusion (DLI) within 28 days Active acute GVHD grades II-IV Active and uncontrolled relapse of malignancy Pregnant or lactating in female patients, if applicable (childbearing potential who have received a reduced intensity conditioning regimen)
Patient description: A 62 yo male presents with four days of non-productive cough and one day of fever. He is on immunosuppressive medications, including prednisone. He is admitted to the hospital, and his work-up includes bronchoscopy with bronchoalveolar lavage (BAL). BAL fluid examination reveals owl's eye inclusion bodies in the nuclei of infection cells.

Clinical trial eligibility criteria: eligible ages (years): 16.0-90.0,  Kidney Transplantation Recipients age 16 or more agree with written informed consent  donor CMV IgG (+) and recipient CMV IgG (-)
Patient description: A 62 yo male presents with four days of non-productive cough and one day of fever. He is on immunosuppressive medications, including prednisone. He is admitted to the hospital, and his work-up includes bronchoscopy with bronchoalveolar lavage (BAL). BAL fluid examination reveals owl's eye inclusion bodies in the nuclei of infection cells.

Clinical trial eligibility criteria: eligible ages (years): 16.0-99.0,  Bone Marrow Transplantation age 16 or more agree with written informed consent
Patient description: A 62 yo male presents with four days of non-productive cough and one day of fever. He is on immunosuppressive medications, including prednisone. He is admitted to the hospital, and his work-up includes bronchoscopy with bronchoalveolar lavage (BAL). BAL fluid examination reveals owl's eye inclusion bodies in the nuclei of infection cells.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Cytomegalovirus Kidney Transplantation CMV Specific Immune Response Patient receiving a kidney graft Recipient being CMV-seropositive prior transplantation and receiving a graft from either a CMV-seropositive or from a seronegative donor (intermediate risk groups, D+/R+; D-/R+,) Patient scheduled to follow the preemptive antiviral strategy with oral valganciclovir or intravenous ganciclovir after transplantation Patient receiving the standard triple immunosuppressive regimen (CNI, MMF/MPA or mTOR inhibitors, steroids), with or without induction therapy (except ATG) as start therapy after transplantation Male or female patient at least 18 years of age Written informed consent  Patient is scheduled for the optional visit 1, but requires ongoing treatment with a systemic immunosuppressive drug already prior to kidney transplantation (except induction therapy other than ATG) Patient receiving ATG as induction therapy Patient is known to be positive for HIV or suffering from chronic hepatitis infections Patient has significant uncontrolled concomitant infections or other unstable medical conditions before transplantation that could interfere with the study objectives Patient is unable to comply with the visit schedule in the protocol Patient has any form of substance abuse, psychiatric disorder or condition that, in the opinion of the investigator may invalidate communication with the investigator
Patient description: A 62 yo male presents with four days of non-productive cough and one day of fever. He is on immunosuppressive medications, including prednisone. He is admitted to the hospital, and his work-up includes bronchoscopy with bronchoalveolar lavage (BAL). BAL fluid examination reveals owl's eye inclusion bodies in the nuclei of infection cells.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Viral Pneumonia mechanical ventilation > 96 hrs and expected duration of mechanical ventilation of at least 2 days positive blood CMV PCR (500 IU/ml) OR positive oropharyngeal HSV PCR age > 18 years informed consent negative pregnancy test  < 18 years Receiving ganciclovir or aciclovir or another antiviral agent active against HSV/CMV Had received antiviral agent active against HSV/CMV during the previous month Hypersensitivity to aciclovir/ganciclovir Pregnancy Breast feeding Bone marrow failure Solid organ recipients Bone marrow recipients HIV positive patients
Patient description: A 62 yo male presents with four days of non-productive cough and one day of fever. He is on immunosuppressive medications, including prednisone. He is admitted to the hospital, and his work-up includes bronchoscopy with bronchoalveolar lavage (BAL). BAL fluid examination reveals owl's eye inclusion bodies in the nuclei of infection cells.

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  HIV COPD Pulmonary Disease Aging Pregnancy or breast-feeding Contraindication to pulmonary function testing (i.e. abdominal or cataract surgery within 3 months, recent myocardial infarction, etc.) Increasing respiratory symptoms or febrile (temperature >100.40F [380C]) within 4 weeks of study entry Hospitalization within 4 weeks prior to study entry Uncontrolled hypertension at screening visit (systolic > 160 mm Hg or diastolic > 100 mm Hg) from an average of two or more readings. Subject may return for screening after blood pressure is controlled Active cancer requiring systemic chemotherapy or radiation Active infection of lungs, brain, or abdomen Intravenous drug use or alcohol use that will impair ability to complete study investigations in the opinion of the investigator  HIV+ young HIV-1 infection, documented in medical record at any time prior to study entry Men and women age 45 years and below Ability and willingness to complete all tests Participant in MACS, Women's Interagency Health Study and secondarily clinics and the community HIV+ old HIV-1 infection, documented in medical record at any time prior to study entry Men and women age 50 years and above Ability and willingness to complete all tests Participant in MACS, Women's Interagency Health Study and secondarily clinics and the community
Patient description: A 62 yo male presents with four days of non-productive cough and one day of fever. He is on immunosuppressive medications, including prednisone. He is admitted to the hospital, and his work-up includes bronchoscopy with bronchoalveolar lavage (BAL). BAL fluid examination reveals owl's eye inclusion bodies in the nuclei of infection cells.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Cytomegalovirus Infection GVHD Patients receiving an allogeneic hematopoietic stem cell transplantation being either CMV seropositive or receiving a graft from a CMV seropositive donor or both, donor and recipient are CMV seropositive (D+/R-, D-/R+, D+/R+) Patients receiving a first allogeneic hematopoietic stem cell graft Patient at least 18 years of age Written informed consent  Seronegativity for CMV both for patient and donor (D-/R-) Patients receiving standard anti-CMV prophylaxis Patients receiving a haploidentical allogeneic hematopoietic stem cell graft Patients receiving an umbilical cord blood graft Patients treated with Alemtuzumab (e.g. Campath) Patient has any form of substance abuse, psychiatric disorder or condition that, in the opinion of the investigator may invalidate communication with the investigator Lack or withdrawal of informed consent Patient is unable to comply with the visit schedule in the protocol
Patient description: A 62 yo male presents with four days of non-productive cough and one day of fever. He is on immunosuppressive medications, including prednisone. He is admitted to the hospital, and his work-up includes bronchoscopy with bronchoalveolar lavage (BAL). BAL fluid examination reveals owl's eye inclusion bodies in the nuclei of infection cells.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Transplantation Infection Cytomegalovirus Infection Age ≥ 18 years End stage kidney disease and a suitable candidate for primary renal transplantation or re-transplantation Patient seropositive for CMV (confirmed within two weeks post-transplant) and having received an allograft from a CMV seropositive or seronegative donor Receiving a kidney transplant from a deceased or living donor with compatible ABO blood type Female subject of childbearing potential must have a negative serum pregnancy test at enrollment and must agree to maintain effective birth control during the study and two months later the discontinuation of the test drug Total ischemia time below 36 hours Capable of understanding the purpose and risks of the study Fully informed and having given written informed consent (signed Informed Consent has been obtained) Affiliation to the social security regimen  CMV seronegative patient Historical or current TGI (French equivalence of calculated PRA) > 85 % Presence of historical or current anti-HLA donor specific antibodies Patient who received anti-CMV therapy within the past 30 days prior to screening Receiving or having previously received an organ transplant other than a kidney Receiving a graft from a non-heart-beating donor Patient known to be positive for Human Immunodeficiency Virus (HIV), Hepatitis B (HBV; HBs Ag positive) or Hepatitis C (HCV; anti-HCV Ab positive).elevated SGPT/ALT and/or SGOT/AST and/or total bilirubin levels ≥ 2 times the upper value of the normal range of the investigational site or receiving a graft from a hepatitis C or B positive donor Significant, uncontrolled concomitant infections and/or severe diarrhea, vomiting, active upper gastro-intestinal tract malabsorption or active peptic ulcer Known allergy or intolerance to everolimus, valganciclovir, ganciclovir, mycophenolic acid, basiliximab, corticosteroids, or cyclosporine A or any of the product excipients Severe hyperlipidemia defined by: total cholestérol ≥ 9,1 mmol/L (≥ 350 mg/dL) et/ou triglycérides ≥ 8,5 mmol/l (≥ 750 mg/dL) in spite an adequate medication
Patient description: A 62 yo male presents with four days of non-productive cough and one day of fever. He is on immunosuppressive medications, including prednisone. He is admitted to the hospital, and his work-up includes bronchoscopy with bronchoalveolar lavage (BAL). BAL fluid examination reveals owl's eye inclusion bodies in the nuclei of infection cells.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Cytomegalovirus Viraemia Adult solid organ transplant (SOT) recipient on at least one immunosuppressive medication Starting therapy for new onset asymptomatic CMV viremia OR starting therapy for new onset CMV disease CMV viral load ≥ 1000 IU/mL  Known ganciclovir-resistant CMV Known intolerance to valganciclovir or ganciclovir Unable to comply with protocol
Patient description: A 62 yo male presents with four days of non-productive cough and one day of fever. He is on immunosuppressive medications, including prednisone. He is admitted to the hospital, and his work-up includes bronchoscopy with bronchoalveolar lavage (BAL). BAL fluid examination reveals owl's eye inclusion bodies in the nuclei of infection cells.

Clinical trial eligibility criteria: eligible ages (years): 2.0-59.0,  Dengue Children who have completed 24 months of age, adolescents and adults who have not completed 60 years of age Agree with periodic contacts, either/or by phone, electronic means, and home visits Show voluntary intention to participate in the study, documented by the participant's or participant's legal representative's signature of the informed consent form  For women: Pregnancy (confirmed by positive beta-hCG test) or breastfeeding Evidence of active neurological, cardiac, pulmonary, hepatic or renal disease as per clinical history and/or physical examination Compromised immune system diseases including: decompensated diabetes mellitus, cancer (except basal cell carcinoma), congenital or acquired immune deficiencies and not controlled autoimmune, as per clinical history and/or physical examination Behavioral, cognitive or psychiatric disease that in the opinion of the principal investigator or his representative physician, affects the participant ability to understand and cooperate with all study protocol requirements Abusive usage of alcohol or drugs in the past 12 months that has caused medical, professional or family problems, indicated by clinical history History of severe allergic reactions or anaphylaxis to the vaccine or to components of the vaccine in study History of asplenia Use of any investigational product within 28 days before or after receiving this study vaccination Has participated in another clinical trial six months prior to in the study or planning to participate in another clinical trial within 2 years following inclusion Use of immunosupressant drugs such as: antineoplastic chemotherapy, radiation therapy, imunossupressants to induce tolerance to transplants, and corticosteroids use (except topical or nasal). For this protocol will be considered for use of corticosteroids 3 months prior to the in the study and 6 months prior to the for the other therapies mentioned, and planned use of any immunesupressant therapy within 2 years following in the study. It will be considered immunosuppressive dose of corticosteroids the equivalent to a dose ≥20 mg of prednisone per day for adults and the equivalent of prednisone at 2 mg/kg/day for children for over 7 days